For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Search Posts
Op-Eds
Needle and the Damage Done
The Supreme Court botches a drug preemption case.
Blog
An Explosion of Litigation
Already burdened by $8 trillion in new federal spending commitments and the likelihood of higher taxes to pay for bailouts,…
Blog
Yes, “Botch” is the right word.
Alex is right. “This IS one of these questions about what to do in the real world, where first-best solutions just aren’t politically possible†(emphasis…
Blog
Did the Supreme Court “Botch” Wyeth v. Levine?
I was initially going to post this as a comment to Greg Conko’s recent post arguing against the Court’s recent decision in Wyeth…
Blog
Supreme Court Botches Preemption Case
Ms. Levine alleged not only that the warning on Phenergan's label wasn't strong enough, but that Phenergan was "not reasonably safe for intravenous administration," and…
Citation